

DÃ³nal Landers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1617858/publications.pdf>

Version: 2024-02-01

16
papers

566
citations

1040056

9
h-index

940533

16
g-index

19
all docs

19
docs citations

19
times ranked

1384
citing authors

#	ARTICLE	IF	CITATIONS
1	Wave comparisons of clinical characteristics and outcomes of COVID-19 admissions - Exploring the impact of treatment and strain dynamics. <i>Journal of Clinical Virology</i> , 2022, 146, 105031.	3.1	9
2	Biomarker identification using dynamic time warping analysis: a longitudinal cohort study of patients with COVID-19 in a UK tertiary hospital. <i>BMJ Open</i> , 2022, 12, e050331.	1.9	10
3	Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital. <i>JCO Clinical Cancer Informatics</i> , 2022, , .	2.1	7
4	Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. <i>Nature Communications</i> , 2022, 13, .	12.8	19
5	Research Evaluation Alongside Clinical Treatment in COVID-19 (REACT COVID-19): an observational and biobanking study. <i>BMJ Open</i> , 2021, 11, e043012.	1.9	12
6	Technology clinical trials: Turning innovation into patient benefit. <i>Digital Health</i> , 2021, 7, 205520762110121.	1.8	2
7	An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. <i>Nature Medicine</i> , 2021, 27, 793-801.	30.7	56
8	Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. <i>Nature Medicine</i> , 2019, 25, 738-743.	30.7	202
9	Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study. <i>Investigational New Drugs</i> , 2017, 35, 451-462.	2.6	44
10	A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 5366-5373.	7.0	109
11	Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT. <i>Advances in Therapy</i> , 2016, 33, 1012-1024.	2.9	6
12	FIESTA: A phase Ib and pharmacokinetic trial of AZD4547 in combination with gemcitabine and cisplatin.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4521-4521.	1.6	4
13	BISCAY, a phase Ib, biomarker-directed multidrug umbrella study in patients with metastatic bladder cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4577-TPS4577.	1.6	8
14	Complexity of FGFR signalling in metastatic urothelial cancer. <i>Journal of Hematology and Oncology</i> , 2015, 8, 119.	17.0	28
15	A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4014-4014.	1.6	36
16	A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GO) cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2620-2620.	1.6	11